Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Financial News

1
Warren Buffett: If you want to be a good investor run a lousy business

1h cnbc
Warren Buffett's holding company, Berkshire Hathaway, is anything but lousy: In 2017, it generated net income of $44.94 billion. But there are advantages to being exposed to struggling businesses, the Berkshire chairman and CEO said at the 2017 Berkshire Hathaway Annual Meeting, adding that it may even make you a better investor: "I really think, if you want to be a good evaluator of businesses — an investor — you really ought to figure out a way, without too much personal damage, to run a lousy business for a while.
BRK.A

 
Smiths Group, ICU Medical in talks on healthcare merger- source

10m reuters
(Reuters) - British engineering firm Smiths Group Plc (SMIN.L) and U.S.-based ICU Medical Inc (ICUI.O) are in talks about a merger of their medical device businesses, a person familiar with the discussions told Reuters.
SMIN SMGZY SMGKF ICUI

 
Buy This 5.7%-Yielding, Monthly-Paying REIT

10m seekingalpha
LTC Properties brings a lot to the table for income investors, including a high-quality, diversified, long-duration lease portfolio, strong portfolio stats, and a low FFO payout ratio.
LTC

 
Toys R Us Bankruptcy Is A Long-Term Benefit For Carter's

21m seekingalpha
Carter's has fallen sharply off all-time highs due in part to the perceived impact of the Toys R Us bankruptcy.
XKE CRI

 
Reader Inquiry: How Has The Thesis Changed For Aimmune Therapeutics?

21m seekingalpha
Some key institutional players are betting on competitor DBV Technologies´ Viaskin Peanut despite the failed trial.
DBV AIMT MRTX

Click for full coverage

Latest Activist 13D and 13G Filings

Every investor that acquires 5% of a company is required to file a beneficial ownership filing, which is either a Form 13D or Form 13G, within ten (10) days of the event. If the investor intends to influence management, then they are considered an activist investor and must file a 13D. There is evidence that suggests investing alongside activist investors is a stock market investing strategy that can produce excess returns. This free screener shows all of the required Schedule 13D filings made by activist investors.

DateFormTargetInvestor SharesOwnership
2018‑05‑25 SC 13D/A SD / Sandridge Energy ICAHN CARL C
2018‑05‑25 SC 13D/A GHL / Greenhill & Co. GREENHILL ROBERT F 2,091,493 8.8
2018‑05‑25 SC 13D ABYLY / Ablynx Sanofi 74,567,835 95.6
2018‑05‑25 SC 13D/A DRIO / DarioHealth Farhi Shmuel 1,115,240 5.8
2018‑05‑25 SC 13D DHX / DHI Group TCS CAPITAL MANAGEMENT LLC 5,002,547 9.7
2018‑05‑25 SC 13D/A VRAY / ViewRay Kearny Venture Partners LP 236,825 0.3
2018‑05‑25 SC 13D FARM / Farmer Brothers Co. LEVIN CAPITAL STRATEGIES, L.P. 1,430,020 8.4
2018‑05‑25 SC 13D/A REG / Regency Centers Gazit-Globe Ltd 8,317,279 4.9
2018‑05‑25 SC 13D/A HLF / Herbalife ICAHN CARL C
2018‑05‑25 SC 13D/A ZIVO / Zivo Bioscience Strome Mark E 27.5
Click for full list

Latest Research Reports

Fintel Research Reports are free Wikipedia-style reports that are created and edited by people just like you. If you are an expert on a company and would like to help your fellow investors make more informed investing decisions, then you should become a Fintel Contributing Analyst. To do this, register on the site, message us in the online chat, and we will get you started.

HRTX : Heron Therapeutics Analysis and Research Report

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

Click for full list

Stock Screens

Stock screens allow users to filter the companies listed on the stock market by various attributse, in order to screen out those that are undesirable. Stock screens on Fintel are made from a rich formula language that allows the utmost flexibility.

The fundamental task in investing is finding mispricings in price v. quality. There are a lot of cheap companies in the market, but most of them are cheap for very good reasons. The trick is finding companies that are cheap but actually healthy. In 2000, Joseph Piotroski wrote a paper in which he described a mathematical model that turned data from financial reports into a simple 9-point score that described a company’s health. He showed that this score, combined with a valuation metric (he used Book-To-Market), could be used successfully to produce excess returns in an investing strategy. This stock screener finds all companies with a score greater than six (which we call “healthy enough”). In his work, he suggested taking a list like this and buying the cheapest of that list. Note that many people believe, incorrectly, that buying companies with the best score is the proper approach, but they end up overpaying for quality. Remember, the goal is to find mispricings in price and quality, not overpay for high quality.  
Companies with Return on Invested Capital (ROIC) > 15%  
Finds all companies with an activist investor filing in the last year  
Finds companies where Price to Book Value < 1.0;  
Companies with negative enterprise value generally get this way because they have a lot of cash. (Cash is subtracted when calculating EV). There is some evidence that negative enterprise value companies outperform the market, so companies matching this screen might be undervalued.  
For investors desiring income over capital appreciation, companies that pay dividends regularly are a great way to generate a steady cash flow. As in any purchase, the goal is to get most value for your dollar, and with dividends, a key metric is dividend yield. The dividend yield is the annual dividend paid divided by the current share price. Higher yields are better. This stock screen finds all securities with a dividend yield greater than 4%.  
This stock screen finds microcap companies with positive annual revenue.  
This is Benjamin Graham's Net Net Working Capital Screen  
The Net Current Asset Value (NCAV) is a conservative valuation metric popularized by Benjamin Graham. To calculate it, simply subtract the total liabilities from a company’s current assets. To calculate NCAVPS (Net Current Asset Value Per Share), divide the NCAV by the number outstanding shares. This stock screener takes Ben Graham’s more conservative approach and uses ⅔ of the NCAV.